{"success":true,"data":{"pressRelease":{"id":"132507","rtpr_id":"nWkrvbLbS","ticker":"ELIC","exchange":"Nasdaq Stockholm","all_tickers":["ELIC"],"title":"Elicera Therapeutics receives its first notice of patent allowance for ELC-201 - a Japanese patent protecting the oncolytic virus candidate against solid tumors","author":"Cision","published_at":"2026-09-01T12:06:20.121Z","article_body":"Elicera Therapeutics\nUppsala, September 1, 2026 - Elicera Therapeutics AB (publ) (\"Elicera\"), a\nclinical stage cell and gene therapy company developing next-generation\ntherapies based on oncolytic viruses and CAR T-cells armed with bystander\nimmune activating properties using the company's commercially available\nplatform iTANK, today announced that it has received a Notice of Allowance\nfrom the Japan Patent Office regarding its patent application for the\noncolytic virus candidate against solid tumors, ELC-201.\n\nThe patent protects Elicera's oncolytic viruses engineered to induce\nimmunogenic cell death of cancer cells, T and NK cell activation and DC\nmaturation, therefore having improved anticancer effect also against solid\ntumors. It gives Elicera exclusive rights in Japan to develop and sell\ntreatments based on ELC-201 for cancer treatment.\n\n\"This first Notice of Allowance for ELC-201, issued by the Japan Patent\nOffice, is an important step in building out global protection for the\ncandidate, following our recent patent success with ELC-401 in US. It\nunderscores the breadth and durability of our iTANK-based pipeline, signals\nthe strength of Elicera's innovation, and gives us a stronger foundation from\nwhich to advance ELC-201\", says Elicera's CEO, Johan Liwing.\n\nFor further information please contact:\nJohan Liwing, CEO, Elicera Therapeutics AB\n\nPhone: +46 (0) 706 70 36 75\njohan.liwing@elicera.com\n\n\nCertified Advisor\nDNB Carnegie Investment Bank AB (publ)\n\nAbout ELC-201\n\nELC-201 is a next-generation oncolytic virus with a combined three\nmode-of-actions in the treatment of cancer. The drug candidate has been\ngenetically modified with the company’s proprietary immune enhancing\nplatform technology, iTANK, in addition to 4-1BBL, both of which lead to\nstrong activation of the patient’s endogenous killer T-cells, leading to a\nbroad parallel attack on cancer cells. ELC-201 is applicable for treatment of\nmost solid tumors.\n\nAbout the iTANK platform\nThe iTANK technology platform has been developed for arming and enhancing CAR\nT-cells to meet two of the major challenges CAR T-cell therapies face in the\ntreatment of solid tumors: a very diverse set of tumor antigen targets and a\nvery hostile tumor microenvironment. The technology is used to incorporate a\ntransgene into CAR T-cells encoding a neutrophil activating bacterial protein\n(NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to\nenhance the function of CAR T-cells and importantly activating a parallel\nbystander immune response against the cancer via CD8+ killer T-cells. This is\nexpected to lead to a broad attack against most antigen targets on cancer\ncells. The iTANK platform is used to enhance the company’s own CAR T-cells\nbut can also be universally applied to other CAR T-cell therapies under\ndevelopment. Proof-of-concept data was published in Nature Biomedical\nEngineering in April 2022. The publication, titled “CAR T cells expressing\na bacterial virulence factor triggers potent bystander antitumor responses in\nsolid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here:\nhttps://www.nature.com/articles/s41551-022-00875-5. More information about\niTANK platform is available here: https://www.elicera.com/technology\n\nAbout Elicera Therapeutics AB\nElicera Therapeutics AB (publ) has developed the patented gene technology\nplatform iTANK that enables the arming of new and existing CAR T-cell\ntherapies targeting aggressive and relapsing cancer forms. Elicera\nTherapeutics thereby addresses a well-defined and vast market. The company’s\nCAR T-cell therapies have shown a potent effect toward solid tumors which are\nrecognized as particularly difficult to treat and constitute the majority of\ncancer cases. The company addresses a global multibillion market in cell\ntherapy through its offering of non-exclusive licensing of the iTANK-platform\nto companies in the pharmaceutical industry. Elicera Therapeutics has four\ninternal development projects in immune therapy that separately have the\npotential to generate substantial value through exclusive out-licensing\nagreements. The company’s share is traded on Nasdaq First North Growth\nMarket. For additional information, visit www.elicera.com.\n\n\n\n\n\nhttps://news.cision.com/elicera-therapeutics/r/elicera-therapeutics-receives-its-first-notice-of-patent-allowance-for-elc-201---a-japanese-patent-p%2Cc4390604\n\nPress release 260901 - 201 JP Allowance\n(https://mb.cision.com/Main/20218/4390604/4246214.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkrvbLbS","title":"Elicera Therapeutics receives its first notice of patent allowance for ELC-201 - a Japanese patent protecting the oncolytic virus candidate against solid tumors","author":"Cision","ticker":"ELIC","created":"2026-09-01T12:06:20.121Z","tickers":["ELIC"],"exchange":"Nasdaq Stockholm","article_body":"Elicera Therapeutics\nUppsala, September 1, 2026 - Elicera Therapeutics AB (publ) (\"Elicera\"), a\nclinical stage cell and gene therapy company developing next-generation\ntherapies based on oncolytic viruses and CAR T-cells armed with bystander\nimmune activating properties using the company's commercially available\nplatform iTANK, today announced that it has received a Notice of Allowance\nfrom the Japan Patent Office regarding its patent application for the\noncolytic virus candidate against solid tumors, ELC-201.\n\nThe patent protects Elicera's oncolytic viruses engineered to induce\nimmunogenic cell death of cancer cells, T and NK cell activation and DC\nmaturation, therefore having improved anticancer effect also against solid\ntumors. It gives Elicera exclusive rights in Japan to develop and sell\ntreatments based on ELC-201 for cancer treatment.\n\n\"This first Notice of Allowance for ELC-201, issued by the Japan Patent\nOffice, is an important step in building out global protection for the\ncandidate, following our recent patent success with ELC-401 in US. It\nunderscores the breadth and durability of our iTANK-based pipeline, signals\nthe strength of Elicera's innovation, and gives us a stronger foundation from\nwhich to advance ELC-201\", says Elicera's CEO, Johan Liwing.\n\nFor further information please contact:\nJohan Liwing, CEO, Elicera Therapeutics AB\n\nPhone: +46 (0) 706 70 36 75\njohan.liwing@elicera.com\n\n\nCertified Advisor\nDNB Carnegie Investment Bank AB (publ)\n\nAbout ELC-201\n\nELC-201 is a next-generation oncolytic virus with a combined three\nmode-of-actions in the treatment of cancer. The drug candidate has been\ngenetically modified with the company’s proprietary immune enhancing\nplatform technology, iTANK, in addition to 4-1BBL, both of which lead to\nstrong activation of the patient’s endogenous killer T-cells, leading to a\nbroad parallel attack on cancer cells. ELC-201 is applicable for treatment of\nmost solid tumors.\n\nAbout the iTANK platform\nThe iTANK technology platform has been developed for arming and enhancing CAR\nT-cells to meet two of the major challenges CAR T-cell therapies face in the\ntreatment of solid tumors: a very diverse set of tumor antigen targets and a\nvery hostile tumor microenvironment. The technology is used to incorporate a\ntransgene into CAR T-cells encoding a neutrophil activating bacterial protein\n(NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to\nenhance the function of CAR T-cells and importantly activating a parallel\nbystander immune response against the cancer via CD8+ killer T-cells. This is\nexpected to lead to a broad attack against most antigen targets on cancer\ncells. The iTANK platform is used to enhance the company’s own CAR T-cells\nbut can also be universally applied to other CAR T-cell therapies under\ndevelopment. Proof-of-concept data was published in Nature Biomedical\nEngineering in April 2022. The publication, titled “CAR T cells expressing\na bacterial virulence factor triggers potent bystander antitumor responses in\nsolid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here:\nhttps://www.nature.com/articles/s41551-022-00875-5. More information about\niTANK platform is available here: https://www.elicera.com/technology\n\nAbout Elicera Therapeutics AB\nElicera Therapeutics AB (publ) has developed the patented gene technology\nplatform iTANK that enables the arming of new and existing CAR T-cell\ntherapies targeting aggressive and relapsing cancer forms. Elicera\nTherapeutics thereby addresses a well-defined and vast market. The company’s\nCAR T-cell therapies have shown a potent effect toward solid tumors which are\nrecognized as particularly difficult to treat and constitute the majority of\ncancer cases. The company addresses a global multibillion market in cell\ntherapy through its offering of non-exclusive licensing of the iTANK-platform\nto companies in the pharmaceutical industry. Elicera Therapeutics has four\ninternal development projects in immune therapy that separately have the\npotential to generate substantial value through exclusive out-licensing\nagreements. The company’s share is traded on Nasdaq First North Growth\nMarket. For additional information, visit www.elicera.com.\n\n\n\n\n\nhttps://news.cision.com/elicera-therapeutics/r/elicera-therapeutics-receives-its-first-notice-of-patent-allowance-for-elc-201---a-japanese-patent-p%2Cc4390604\n\nPress release 260901 - 201 JP Allowance\n(https://mb.cision.com/Main/20218/4390604/4246214.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-09-01T12:06:20.218679099Z","server_sent_at_ms":1788264380218},"received_at":"2026-09-01T12:06:20.305Z","source_url":"https://news.cision.com/elicera-therapeutics/r/elicera-therapeutics-receives-its-first-notice-of-patent-allowance-for-elc-201---a-japanese-patent-p%2Cc4390604"},"analysis":{"id":"121409","press_release_id":"132507","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Elicera Therapeutics received a Notice of Allowance from the Japan Patent Office for its patent application covering ELC-201, an oncolytic virus candidate targeting solid tumors.\n\nThe patent provides exclusive rights in Japan to develop and sell treatments based on ELC-201, marking a step in building global protection for the company's pipeline.\n\nCEO Johan Liwing noted that this allowance follows recent patent success for ELC-401 in the US and underscores the durability of the iTANK-based platform.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Japanese patent allowance strengthens IP position for solid tumor candidate ELC-201."},"keyFigures":null,"quotedText":"This first Notice of Allowance for ELC-201, issued by the Japan Patent Office, is an important step in building out global protection for the candidate, following our recent patent success with ELC-401 in US.","namedEntities":{"people":[{"name":"Johan Liwing","role":"CEO"}],"products":["ELC-201","ELC-401","iTANK"],"companies":[{"name":"Elicera Therapeutics AB (publ)","ticker":"ELIC"},{"name":"DNB Carnegie Investment Bank AB (publ)","relationship":"Certified Advisor"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Receipt of a Japanese patent notice of allowance for ELC-201 strengthens global IP protection but represents a standard administrative milestone for a clinical-stage biotech without immediate revenue or binary clinical impact."},"tickerRelevance":{"others":[],"primary":"ELIC"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"ip-milestone","sectorWeight":"biotech","marketCapAdjustment":"small-cap瑞典"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Elicera Therapeutics received a Notice of Allowance from the Japan Patent Office for its patent application covering ELC-201, an oncolytic virus candidate targeting solid tumors.\n\nThe patent provides exclusive rights in Japan to develop and sell treatments based on ELC-201, marking a step in building global protection for the company's pipeline.\n\nCEO Johan Liwing noted that this allowance follows recent patent success for ELC-401 in the US and underscores the durability of the iTANK-based platform.","key_figures":null,"named_entities":{"people":[{"name":"Johan Liwing","role":"CEO"}],"products":["ELC-201","ELC-401","iTANK"],"companies":[{"name":"Elicera Therapeutics AB (publ)","ticker":"ELIC"},{"name":"DNB Carnegie Investment Bank AB (publ)","relationship":"Certified Advisor"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T13:49:43.795Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"ip-milestone","sectorWeight":"biotech","marketCapAdjustment":"small-cap瑞典"}},"durationMs":319260,"modelName":"glm-4.7"}}